Skip to main content
Publications
Anthony L, Ervin C, Lapuerta P, Kulke MH, Kunz P, Bergsland E, Horsch D, Metz DC, Pasieka J, Pavlakis N, Pavel M, Caplin M, Oberg K, Ramage J, Evans E, Yang QM, Jackson S, Arnold K, Law L, DiBenedetti DB. Understanding the patient experience with carcinoid syndrome: exit interviews from a randomized, placebo-controlled study of telotristat ethyl. Clin Ther. 2017 Nov 11;39(11):2158-68. doi: 10.1016/j.clinthera.2017.09.013
Twiss J, Balp M, Doward L, Slota C, Cryer D, Langford A, Collen R, Agashivala N, Brass C, Sanyal A, Anstee QM. Development of a new patient-reported outcome measure for non-alcoholic steatohepatitis: NASH-check. Poster presented at the 2017 ISPOR 20th Annual European Congress; November 7, 2017. Glasgow, Scotland.
Emery P, van Keep M, Beard SM, Graham CN, Miles L, Jugl SM, Gunda P, Halliday A, Marzo-Ortega H. Cost-effectiveness of secukinumab for the treatment of active ankylosing spondylitis in the UK. Poster presented at the 2017 ISPOR 20th Annual European Congress; November 6, 2017. Glasgow, Scotland.
Mease PJ, Gladman DD, Davenport EK, Zhou X, Guerette B, Teng L, Kaura S, Nash P. Improvements in work productivity with up to 104 weeks of apremilast monotherapy: results from a phase 3b, randomized, controlled study in biologic-naive subjects with active psoriatic arthritis. Poster presented at the 2017 ACR/ARHP Annual Meeting; November 5, 2017. San Diego, CA.
Druce KL, McBeth J, van der Veer SN, Selby DA, Vidgen B, Georgatzis K, Hellman B, Lakshminarayana R, Chowdhury A, Schultz DM, Sanders C, Sergeant JC, Dixon WG. Recruitment and ongoing engagement in a UK smartphone study examining the association between weather and pain: cohort study. JMIR Mhealth Uhealth. 2017 Nov 1;5(11):e168. doi: 10.2196/mhealth.8162
Herring W, Zhang Y, Pearson I, Tempest M, Freudensprung U, Acosta C, Hyde R, Spelman T, Butzkueven H. A cost-effectiveness analysis using real-world data from the MSBase registry: comparing natalizumab to fingolimod in patients with inadequate response to disease modifying therapies in relapsing-remitting multiple sclerosis in Scotland. Poster presented at the 7th Joint ECTRIMS-ACTRIMS Meeting; October 26, 2017. Paris, France.
Arana A, Huerta C, Prieto D, Montero D, Hermosilla E, Martin E, Mendez L, del Mar Garcia M, Comas M, Giner M, Macia MA, Morros R, Duarte T. Uso de datos basados en historia clinica informatizada ('real world data') en los estudios farmaco-epidemiologicos. Presented at en IDIAP Jordi Gol Conference; October 23, 2017. Barcelona, Spain.
Danysh H, Brown A, Taylor O, Brackett J, Lupo P, Moore I, Hooke MC, Hockenberry M, Scheurer M. Impact of acute methotrexate-induced neurotoxicity on therapy among pediatric patients with acute lymphoblastic leukemia. Poster presented at the 49th Congress of the International Society of Paediatric Oncology; October 13, 2017. Washington, DC.
Patterson BJ, Buck PO, Carrico J, Hicks KA, Curran D, Van Oorschot D, Pawlowski JE, Lee BY, Yawn BP. Assessment of the potential herpes zoster and post herpetic neuralgia case avoidance with vaccination in the United States. Poster presented at the IDWeek 2017 Conference; October 6, 2017. San Diego, CA.
Nance R, Vannappagari V, Johannes C, Calingaert B, Saltus C, Boswell S, Rodriguez B, Moore R, Eron J, Geng E, Mathews WC, Saag MS, Kitahata M, Delaney JAC, Crane HM, Centers For AIDS Research Network of Integrated Clinical Systems (CNICS). Viral failure among persons living with HIV initiating dolutegravir-based vs. other recommended regimens in real-world clinical care settings. Poster presented at the IDWeek 2017 Conference; October 2017. San Diego, CA. [abstract] Open Forum Infect Dis. 2017 Oct 4; 4((Suppl 1)):S39. doi: 10.1093/ofid/ofx162.095